MULTIPLE MYELOMA KNOWLEDGE CENTER

How is Marizomib currently being studied in myeloma?

Marizomib is being studied, alone and in combination with dexamethasone, in patients with relapsed or relapsed/refractory myeloma in an ongoing phase I trial that is being facilitated by the Multiple Myeloma Research Consortium (MMRC). Preliminary results from this study and a study in Australia suggest that NPI-0052 is generally well tolerated and displays clinical activity, with responses seen in patients whose disease stopped responding to Velcade. Peripheral neuropathy, a side effect sometimes seen with the proteasome inhibitor Velcade, was infrequent.